One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Dermato-venereology in the year of coronavirus – Hot topics in research and patient care
J. Ring
doi : 10.1111/jdv.17087
Volume 35, Issue 1 p. 8-10
Another beneficial effect of phototherapy
B. Eberlein
doi : 10.1111/jdv.17073
Volume 35, Issue 1 p. 11-12
Sun exposure exerts many effects on humans. Particularly affected is the skin whose structures interact with the irradiation. Effects of solar radiation on human health can be beneficial and adverse. Among the latter ones are sunburn, skin ageing and especially skin cancer that is still rising in Europe.1 On the other hand, vitamin D production resulting from UVB exposure is necessary for bone health, particularly by virtue of its enhancement of calcium and phosphate absorption. As there are further positive effects of sun exposure, the risks and benefits have to be balanced.
Place of apremilast in the real-life treatment of patients with plaque psoriasis
P. Gisondi, D. Geat, G. Girolomoni
doi : 10.1111/jdv.17067
Volume 35, Issue 1 p. 13-13
In this issue of the Journal, Augustin et al.1 published the results of the APPRECIATE study, that is a multinational, observational, retrospective, cross-sectional study in patients treated with apremilast. The objective of the study was to describe the characteristics of patients with psoriasis (n = 480) treated with apremilast in real life, to evaluate its efficacy and safety and to better understand the perspectives of patients and physicians on the treatment. The mean (SD) baseline PASI score was 12.5 (8.4), and the rate of patients with a PASI score<10 was 40%. The proportion of patients who had received a prior treatment with phototherapy, conventional systemic therapies or biologic was 56.3%, 68.3% and 15%. These finding suggest us that the real-life place in therapy of apremilast in patients with psoriasis is most frequently after phototherapy or conventional systemic therapies in those patients who are not candidate to biologic drugs yet. This patients’ population, which has been classified as ‘moderate’ in disease severity, still perceive a high disease burden on their quality of life despite a PASI score <10.2 Indeed, the burden of psoriasis is not completely captured by the PASI. Many other factors can contribute to it, such as severity of symptoms (e.g. pruritus), the embarrassment of having psoriasis on visible or sensitive areas, the frustration of long-standing disease and previous treatment failures, and the inconvenience of complex topical regimens.3, 4 Another important finding of the study is that dermatologists observed a clinical improvement in 75.6% of patients, with 48.6% achieving PASI75 and being 72.3% those who continued apremilast at 6 months. These efficacy data are consistent with the findings of phase 3 clinical trials.5, 6 Notably, patients' perception on the treatment with apremilast was also very positive, with 31% of patients achieving and 22.7% exceeding expectations about the treatment. The reassuring drug's safety profile was also confirmed,5, 6 with the most reported adverse effects being diarrhoea, nausea and headache occurring in 18%, 14% and 8% of patients, respectively. No new safety signals were noted. We agree with the final statements of the authors that in clinical practice patients who initiated apremilast had more moderate skin involvement than those who were enrolled in clinical trials, and they are a different patient's population from those who are candidate to biologics. Given its impact on quality of life, moderate psoriasis in many instances needs to be managed not with topicals alone, but with systemic drugs. Oral drugs fit very well in this patients' population as they are easier to prescribe and more likely to be accepted by patients, particularly if the safety profile is favourable and no laboratory monitoring is required, as it is the case for apremilast. Finally, we would like to value the real-world studies because they can extend the existing knowledge of the utility of new treatments by focusing on the acceptability and feasibility of everyday use.
Pioneers in Dermatology and Venereology: an interview with Prof. Gerd Plewig
G. Plewig
doi : 10.1111/jdv.17097
Volume 35, Issue 1 p. 14-16
2020 European guideline on the management of genital molluscum contagiosum
S Edwards, MJ Boffa, M Janier, P Calzavara-Pinton, C Rovati, CM Salavastru, F Rongioletti, A Wollenberg, AI Butacu, M Skerlev, GS Tiplica
doi : 10.1111/jdv.16856
Volume 35, Issue 1 p. 17-26
Molluscum contagiosum is a benign viral epidermal infection associated with high risk of transmission. The guideline isfocused on the sexually transmitted molluscum contagiosum. The diagnosis is clinical with characteristic individuallesions, termed ‘mollusca’, seen as dome-shaped, smooth-surfaced, pearly, ?rm, skin-coloured, pink, yellow or whitepapules, 2 - 5 mm in diameter with central umbilication. Dermoscopy may facilitate diagnosis. Therapeutic options arenumerous, including physical treatments (cautery, curettage and cryotherapy), topical chemical treatments (e.g.podophyllotoxin and imiquimod) or waiting for spontaneous resolution in immunocompetent patients. In pregnancy, it issafe to use physical procedures (e.g. cryotherapy). Immunosuppressed patients develop severe and recalcitrant mollus-cum lesions that may require treatment with cidofovir, imiquimod or interferon. Patients with molluscum contagiosuminfection should be offered to be screened for other sexually transmitted infections.
European dermatology forum: Updated guidelines on the use of extracorporeal photopheresis 2020 – Part 2
R. Knobler, P. Arenberger, A. Arun, C. Assaf, M. Bagot, G. Berlin, A. Bohbot, P. Calzavara-Pinton, F. Child, A. Cho, L.E. French, A.R. Gennery, R. Gniadecki, H.P.M. Gollnick, E. Guenova, P. Jaksch, C. Jantschitsch, C. Klemke, J. Ludvigsson, E. Papadavid, J. Scarisbrick, T. Schwarz, R. Stadler, P. Wolf, J. Zic, C. Zouboulis, A. Zuckermann, H. Greinix
doi : 10.1111/jdv.16889
Volume 35, Issue 1 p. 27-49
Following the first investigational study on the use of extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma published in 1983, this technology has received continued use and further recognition for additional earlier as well as refractory forms. After the publication of the first guidelines for this technology in the JEADV in 2014, this technology has maintained additional promise in the treatment of other severe and refractory conditions in a multidisciplinary setting. It has confirmed recognition in well-known documented conditions such as graft-vs.-host disease after allogeneic bone marrow transplantation, systemic sclerosis, solid organ transplant rejection including lung, heart and liver and to a lesser extent inflammatory bowel disease.
Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life
T.V. Nguyen, G. Damiani, L.A.V. Orenstein, I. Hamzavi, G.B. Jemec
doi : 10.1111/jdv.16677
Volume 35, Issue 1 p. 50-61
Hidradenitis suppurativa (HS) is a chronic in?ammatory skin disease that severely impairs patients’ quality of life. It ischaracterized by recurrent painful nodules, abscesses and draining sinus tracts in primarily intertriginous areas. Weaimed to review the most up-to-date information regarding the epidemiology, clinical presentation, diagnostic studies,pathogenesis, comorbidities and quality of life of patients with hidradenitis suppurativa. We performed a systematicsearch of Medline, Embase database (from inception to September 2019) and review of bibliographies without restric-tions on year or language. HS has an estimated global prevalence of 0.00033–4.1% (but most likely 0.7–1.2% in theEuropean-US population). Patients still experience a signi?cant diagnostic delay, up to several years. In the absence ofpathognomonic tests, the diagnosis of HS is made from clinical observation and the disease narrative. Phenotypic varia-tion renders diagnosis and severity assessment dif?cult. Ultrasound imaging is an emerging assessment tool for deep-seated lesions. The Hurley Staging System is still widely used in severity rating. Follicular hyperkeratosis and dilatation,follicular rupture and chronic in?ammation with architectural tissue changes have been implicated in the pathogenesis ofHS. HS has been associated with metabolic syndrome and other risk factors for cardiovascular disease, diabetes melli-tus type II, polycystic ovarian syndrome, depression, suicide and substance use disorders. It has been linked to otherimmune-mediated diseases such as in?ammatory bowel disease and spondyloarthropathy. Pain, pruritus, malodour, lowself-esteem, sleep and sexual dysfunctions, and poor mental health are chronic symptoms or consequences of uncon-trolled disease. HS is an under-diagnosed and under-treated disease with a profound negative impact on patients’ qual-ity of life. In the light of its associated comorbidities, an interdisciplinary management approach may be needed toensure the best outcomes
Demodex: a skin resident in man and his best friend
R. Foley, P. Kelly, S. Gatault, F. Powell
doi : 10.1111/jdv.16461
Volume 35, Issue 1 p. 62-72
Demodex mites are microscopic arachnids found in the normal skin of many mammals. In humans, it is well establishedthat Demodex mite density is higher in patients with the skin condition rosacea, and treatment with acaricidal agents iseffective in resolving symptoms. However, pathophysiology of rosacea is complex and multifactorial. In dogs, demodi-cosis is a signi?cant veterinary issue, particularly the generalized form of the disease which can be fatal if untreated. Ineach species, clinical and molecular studies have shown that the host’s immunological interactions with Demodex mitesare an important, but not fully understood, aspect of how Demodex can live in the skin either as a harmless commensalorganism or as a pathogenic agent. This review outlines the role of Demodex mites in humans and dogs, consideringmorphology, prevalence, symptoms, diagnosis, histology treatment and pathogenesis
Antibiotic resistance in acne: changes, consequences and concerns
A.S. Karadag, M. Aslan Kay?ran, C.-Y. Wu, W. Chen, L.C. Parish
doi : 10.1111/jdv.16686
Volume 35, Issue 1 p. 73-78
Antibiotic resistance in acne was ?rst observed in the 1970s and has been a major concern in dermatology since the1980s. The resistance rates and types of antimicrobials have subsequently shown great variations in regions and coun-tries. Illustrative of this is the resistance to topical erythromycin and clindamycin which continues to be a problem world-wide, while resistance to systemic treatment with tetracyclines has remained low during the past decade. The resistancefor the newer macrolides like azithromycin and clarithromycin has been increasing. The results of antibiotic resistancemay include treatment failure of acne, disturbance of skin microbiota, induction of opportunistic pathogens locally andsystemically, and dissemination of resistant strains to both healthcare personnel and the general population. The ensu-ing complications, such as aggravated opportunistic infections caused by Propionibacterium acnes and the emergenceof multiresistant superbugs, have not yet been con?rmed
Sclerodermiform basal cell carcinomas vs. other histotypes: analysis of specific demographic, clinical and dermatoscopic features
C. Conforti, M.A. Pizzichetta, S. Vichi, F. Toffolutti, D. Serraino, N. Di Meo, R. Giuffrida, T. Deinlein, J. Giacomel, C. Rosendahl, J.Y. Gourhant, I. Zalaudek
doi : 10.1111/jdv.16597
Volume 35, Issue 1 p. 79-87
Background Among the various types of basal cell carcinoma, the sclerodermiform variant has a high risk of recur-rence and local invasiveness. A systematic description of the dermatoscopic features associated with speci?c bodylocalization is lacking
Metabolic reprogramming and angiogenesis in primary cutaneous Merkel cell carcinoma: expression of hypoxia-inducible factor-1? and its central downstream factors
F. Toberer, H.A. Haenssle, M. Heinzel-Gutenbrunner, A. Enk, W. Hartschuh, P. Helmbold, H. Kutzner
doi : 10.1111/jdv.16600
Volume 35, Issue 1 p. 88-94
Metabolic reprogramming and altered gene expression mediated by hypoxia-inducible factors play crucial roles during tumour growth and progression. Nevertheless, studies analysing the expression of hypoxia-inducible factor-1? and its downstream targets in Merkel cell carcinoma (MCC) are lacking but are warranted to shed more light on MCC pathogenesis and to potentially provide new therapeutic options.
Frailty screening in dermato-oncology practice: a modified Delphi study and a systematic review of the literature
M.E.C. van Winden, S. Garcovich, K. Peris, G. Colloca, E.M.G.J. de Jong, M.E. Hamaker, P.C.M. van de Kerkhof, S.F.K. Lubeek
doi : 10.1111/jdv.16607
Volume 35, Issue 1 p. 95-104
Appropriate management and prevention of both under- and overtreatment in older skin cancer patients can be challenging. It could be helpful to incorporate frailty screening in dermato-oncology care, since frailty is associated with adverse health outcomes.
Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real-world setting
I. Krakowski, M. Bottai, H. H?bel, G. Masucci, A. Girnita, K.E. Smedby, H. Eriksson
doi : 10.1111/jdv.16678
Volume 35, Issue 1 p. 105-115
The survival in metastatic melanoma has dramatically improved after the introduction of immune checkpoint- (ICIs) and MAPKinase inhibitors (MAPKis).
Histopathological predictor of the progression from actinic keratosis to squamous cell carcinoma: quantitative computer-aided image analysis
D.Y. Lee, B.R. Kim, S. Yang, M. Kim, T.Y. Yoon, S.W. Youn
doi : 10.1111/jdv.16680
Volume 35, Issue 1 p. 116-122
The current histopathological classifications for actinic keratosis (AK) are subjective, and histopathologi-cal factors predicting the progression into invasive squamous cell carcinoma (SCC) remain unclear.
Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study
M. Augustin, C.E. Kleyn, C. Conrad, P.G. Sator, M. St?hle, K. Eyerich, M.A. Radtke, C. Bundy, L. Mellars, C. Greggio, M. Cordey, V. Koscielny, C.E.M. Griffiths
doi : 10.1111/jdv.16431
Volume 35, Issue 1 p. 123-134
APPRECIATE is a multinational, observational, retrospective, cross-sectional study in patients treated for psoriasis with apremilast, an oral phosphodiesterase 4 inhibitor.
Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY)
J. Bagel, A. Blauvelt, J. Nia, P. Hashim, M. Patekar, A. de Vera, K. Ahmad, B. Paguet, S. Xia, E. Muscianisi, M. Lebwohl
doi : 10.1111/jdv.16558
Volume 35, Issue 1 p. 135-142
Secukinumab demonstrated superior efficacy over ustekinumab in the treatment of moderate to severe plaque psoriasis over 16 weeks in the CLARITY study and over 52 weeks in the CLEAR study.
Non-invasive clinical and microscopic evaluation of the response to treatment with clobetasol cream vs. calcipotriol/betamethasone dipropionate foam in mild to moderate plaque psoriasis: an investigator-initiated, phase IV, unicentric, open, randomized clinical trial
O. Yélamos, B. Alejo, S. S. Ertekin, L. Villa-Crespo, S. Zamora-Barquero, N. Martinez, M. Dom?nguez, P. Iglesias, A. Herrero, J. Malvehy, S. Puig
doi : 10.1111/jdv.16559
Volume 35, Issue 1 p. 143-149
Treatment response for psoriasis is typically evaluated using clinical scores. However, patients can relapse after clinical clearance, suggesting persistent inflammation. Dermoscopy, reflectance confocal microscopy (RCM) and optical coherence tomography (OCT) can non-invasively improve treatment response assessment.
Identification of a TH2-high psoriasis cluster based on skin biomarker analysis in a Chinese psoriasis population
J. Chen, C. Li, H. Li, H. Yu, X. Zhang, M. Yan, Y. Guo, Z. Yao
doi : 10.1111/jdv.16563
Volume 35, Issue 1 p.150-158
Psoriasis is an immune-mediated, chronic inflammatory disease with diverse phenotypes. However, itsbiological diversity has not been well-characterized in Chinese psoriasis populatio
Systemic therapies for Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: a SCORTEN-based systematic review and meta-analysis
I. Torres-Navarro, ?. Briz-Red?n, R. Botella-Estrada
doi : 10.1111/jdv.16685
Volume 35, Issue 1 p.159-171
The SCORTEN score is a speci?c predictor of mortality for patients with Stevens–Johnson syndrome(SJS)/toxic epidermal necrolysis (TEN). There is little evidence in support of the common immunomodulating therapiesfor SJS/TEN
Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study
A.T. Touhouche, M. Cassagne, E. Bérard, F. Giordano-Labadie, A. Didier, P. Fournié, C. Paul, M. Tauber
doi : 10.1111/jdv.16724
Volume 35, Issue 1 p.172-1719
Dupilumab is approved for use in moderate-to-severe atopic dermatitis (AD) and as an add-on maintenance treatment in patients suffering from severe asthma with type 2 inflammation. Ocular adverse events (OAEs) have been reported with dupilumab almost exclusively in patients treated for AD.
Measurement properties of the product of investigator’s global assessment and body surface area in children and adults with atopic dermatitis
J.I. Silverberg, D. Lei, M. Yousaf, S.R. Janmohamed, P.P. Vakharia, R. Chopra, R. Chavda, S. Gabriel, K.R. Patel, V. Singam, R. Kantor, D.Y. Hsu
doi : 10.1111/jdv.16846
Volume 35, Issue 1 p.180-187
Multiple clinician-reported outcome measures exist for atopic dermatitis (AD) severity. However, there is no gold standard for use in clinical practice.
Chronic pain: a long-term sequela of epidermal necrolysis (Stevens–Johnson syndrome/toxic epidermal necrolysis) – prevalence, clinical characteristics and risk factors
J.-P. Lefaucheur, L. Valeyrie-Allanore, S. Ng Wing Tin, G. Abgrall, A. Colin, C. Hajj, N. de Prost, P. Wolkenstein, S. Ingen-Housz-Oro, O. Chosidow
doi : 10.1111/jdv.16891
Volume 35, Issue 1 p.188-194
Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are associated with various sequelae. Chronic pain, one of these sequelae, has never been systematically evaluated.
Risk of connective tissue disease, morphoea and systemic vasculitis in patients with hidradenitis suppurativa
M.C. Schneeweiss, J.F. Merola, S. Schneeweiss, R. Wyss, D. Rosmarin
doi : 10.1111/jdv.16728
Volume 35, Issue 1 p.195-202
Hidradenitis suppurativa (HS) has been associated with auto-inflammatory conditions, yet the risk of developing connective tissue disease (CTD), morphoea and systemic vasculitis has not been well-characterized.
Increased expression profile of NCSTN, Notch and PI3K/AKT3 in hidradenitis suppurativa
S. Hessam, T. Gambichler, M. Skrygan, L. Scholl, M. Sand, T. Meyer, E. Stockfleth, F.G. Bechara
doi : 10.1111/jdv.16962
Volume 35, Issue 1 p. 203-210
In a small number of kindreds with familial hidradenitis suppurativa (HS) different mutations of NCSTN (nicastrin) have been identified. Blocking of NCSTN leads to impairment of the Notch and PI3K/AKT signalling pathway, which is assumed to play a pathogenic role in HS. However, very limited data are available concerning expression levels of these pathway components in HS skin.
Treatment of granuloma annulare and related granulomatous diseases with sulphasalazine: a series of 16 cases
Y.W. Yang, M.D. Lehrer, A.R. Mangold, J.A. Yiannias, S.A. Nelson, M.R. Pittelkow
doi : 10.1111/jdv.16356
Volume 35, Issue 1 p. 211-215
Granuloma annulare (GA) and the related annular elastolytic giant cell granuloma (AEGCG) and interstitial granulomatous dermatitis (IGD) are idiopathic histiocytic inflammatory disorders, which are frequently recalcitrant to treatment.
Validation of a Patient Global Assessment for extent, severity and impact to define the severity strata for the Self Assessment Vitiligo Extent Score (SA-VES)
N. van Geel, S.E. Uitentuis, M. Zuidgeest, A. Wolkerstorfer, M.W. Bekkenk, C. Moock, C. Van Goethem, E. Verlaeckt, C. Smet, L. Grine, R. Speeckaert
doi : 10.1111/jdv.16562
Volume 35, Issue 1 p. 216-221
The Self Assessment Vitiligo Extent Score (SA-VES) is a validated, patient-reported outcome measure to assess the body surface area affected with vitiligo. Information on how to translate the obtained score into extent, severity and impact strata (mild–moderate–severe) is still lacking. Stratification is helpful to define inclusion criteria for trials, enables comparison and pooling of trial results and can be used for epidemiological research.
Both cardiovascular and cerebrovascular events are decreased following long-term narrowband ultraviolet B phototherapy in patients with vitiligo: a propensity score matching analysis
J.M. Bae, Y.-S. Kim, E.H. Choo, M.-Y. Kim, J.Y. Lee, H.-O. Kim, Y.M. Park
doi : 10.1111/jdv.16830
Volume 35, Issue 1 p. 222-229
Systemic effects of long-term narrowband ultraviolet B (NB-UVB) phototherapy have not been well studied in vitiligo patients. An 11-year nationwide population-based retrospective cohort study was conducted using the Korean National Health Insurance claims database (2007–2017).
The significance of dermoscopy and trichoscopy in differentiation of erythroderma due to various dermatological disorders
M. S?awi?ska, M. Soko?owska-Wojdy?o, M. Sobjanek, J. Goli?ska, R.J. Nowicki, L. Rudnicka
doi : 10.1111/jdv.16998
Volume 35, Issue 1 p. 230-240
The diagnosis of a patient with erythroderma may be difficult and sometimes pose a challenge for both dermatologist and pathologist. The role of dermoscopy in this area seems to be poorly investigated. There are only a few reports, with limited number of patients, describing dermoscopic features in erythroderma of various origins. To the best of our knowledge, none of the previous studies had included trichoscopic examination.
Sexual behaviour, STI knowledge and Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) prevalence in an asymptomatic cohort in Ruhr-area, Germany: PreYoungGo study
A. Skaletz-Rorowski, A. Potthoff, S. Nambiar, J. Wach, A. Kayser, A. Kasper, N.H. Brockmeyer
doi : 10.1111/jdv.16913
Volume 35, Issue 1 p. 241-246
STIs present a significant threat to individual and public health, disproportionately affecting youth. The study aimed to evaluate (a) the prevalence of asymptomatic Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections among youth using a rapid assay platform, (b) the participants' sexual behaviour and STI knowledge, (c) the utility of the rapid assay in reducing diagnosis-to-treatment time.
Comparing the use of a novel antibiotic-free film-forming topical wound dressing versus a topical triple antibiotic in dermatologic surgical procedures including Mohs micrographic surgery
A.V. Benedetto, J.P. Staidle, J. Schoenfeld, E.A. Benedetto, P.X. Benedetto
doi : 10.1111/jdv.16965
Volume 35, Issue 1 p. 247-255
There is no universally accepted protocol of topical wound care after cutaneous surgical procedures. The current practice is to use petrolatum-based products, commonly containing topical antibiotics. The rise in antibiotic-resistant bacteria and increased risk of allergic and contact dermatitis due to the use of topical antibiotics is well established.
Different injection patterns of incobotulinumtoxinA for crow’s feet: a split-face comparative study
V. Vachiramon, U. Subpayasarn, K. Triyangkulsri, N. Jurairattanaporn, T. Rattananukrom
doi : 10.1111/jdv.16997
Volume 35, Issue 1 p. 256-262
IncobotulinumtoxinA has been previously used for the treatment of lateral periorbital lines (crow’s feet). However, a standardized injection technique has not been established.
Corrigendum: A novel mutation in the KCNJ8 gene encoding the Kir6.1 subunit of an ATP-sensitive potassium channel in a Japanese patient with Cant? syndrome
M. Chihara, A. Asahina, M. Itoh
doi : 10.1111/jdv.17015
Volume 35, Issue 1 p. 263-263
Clinical characteristics and outcomes in patients with COVID-19 and leprosy
V. S. Santos, L. J. Quintans-J?nior, W. S. Barboza, A. A. de S. Ara?jo, P. R. Martins-Filho
doi : 10.1111/jdv.16899
Volume 35, Issue 1 p. e1-e2
Chilblains and COVID-19: further evidence against a causal association
M. Baeck, C. Peeters, A. Herman
doi : 10.1111/jdv.16901
Volume 35, Issue 1 p. e2-e3
Skin manifestations in COVID-19 provide a clue for disease's pathophysiology understanding
A.A. Kubanov, D.G. Deryabin
doi : 10.1111/jdv.16902
Volume 35, Issue 1 p. e3-e4
Generalized pustular figurate erythema first report in two COVID-19 patients on hydroxychloroquine
I. Abad?as-Granado, A.M. Palma-Ruiz, P.A. Cerro, A.M. Morales-Callaghan, M.C. G?mez-Mateo, Y. Gilaberte, R.A. Schwartz
doi : 10.1111/jdv.16903
Volume 35, Issue 1 p. e5-e7
How the use of surgical masks during COVID-19 pandemic can induce skin effects
S. Veronese, P. Bernardi, A. Sbarbati
doi : 10.1111/jdv.16905
Volume 35, Issue 1 p. e7-e8
Frequent handwashing and disinfection: a potential new trigger for aquagenic wrinkling of the palms caused by COVID-19 outbreak
Y. Tai, T. Fukumoto, M. Oka, C. Nishigori
doi : 10.1111/jdv.16906
Volume 35, Issue 1 p. e9-e10
Are SARS-CoV-2 IgA antibodies in paediatric patients with chilblain-like lesions indicative of COVID-19 asymptomatic or paucisymptomatic infection?
A. Diociaiuti, S. Giancristoforo, S. Terreri, M. Corbeddu, C. Concato, M. Ciofi Degli Atti, G. Zambruno, R. Carsetti, M. El Hachem
doi : 10.1111/jdv.16934
Volume 35, Issue 1 p. e10-e13
Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men
A. Goren, C.G. Wambier, S. Herrera, J. McCoy, S. Va?o-Galv?n, F. Gioia, B. Comeche, R. Ron, S. Serrano-Villar, P.M. Ramos, F.A. Cadegiani, M. Kovacevic, A. Tosti, J. Shapiro, R. Sinclair
doi : 10.1111/jdv.16953
Volume 35, Issue 1 p. e13-e15
Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients
J. McCoy, C.G. Wambier, S. Herrera, S. Va?o-Galv?n, F. Gioia, B. Comeche, R. Ron, S. Serrano-Villar, R.M. Iwasiow, M.A. Tayeb, F.A. Cadegiani, N.A. Mesinkovska, J. Shapiro, R. Sinclair, A. Goren
doi : 10.1111/jdv.16956
Volume 35, Issue 1 p. e15-e17
Effects of lockdown on health of patients with severe atopic dermatitis treated with dupilumab
S.M. Ferrucci, S. Tavecchio, E.M. Favale, L. Angileri, D. Riva, M. Romagnuolo, A.E. Beretta, A.V. Marzano
doi : 10.1111/jdv.16955
Volume 35, Issue 1 p. e17-e18
Immediate hypersensitivity reaction to ixekizumab in a patient with psoriasis
L. Donzier, T. Deschamps, P. Pralong, F. Skowron
doi : 10.1111/jdv.16748
Volume 35, Issue 1 p. e18-e19
Neutrophilic dermatosis of the dorsal hands triggered by mechanical trauma
A.D. Gloor, L. Feldmeyer, L. Borradori
doi : 10.1111/jdv.16750
Volume 35, Issue 1 p. e20-e21
The risk of leprosy in patients using immunobiologics and conventional immunosuppressants for the treatment of dermatological and rheumatological diseases: a cohort study
C. Martins Gomes, M. Vicente Cesetti, L. Sevilha-Santos, G. Aires Martins, M.S. Cochrane Feitosa, V. Medeiros-Silva, N.A. de Paula, N. Ribeiro de Magalh?es Alves, N. Gil-Jaramilo, C. Nunes de Ara?jo, M.A. Cipriani Frade, L.M.H. da Mota, E. Freitas da Silva, P. Shu Kurizky
doi : 10.1111/jdv.16764
Volume 35, Issue 1 p. e21-e24
Minoxidil Sulfotransferase Enzyme (SULT1A1) genetic variants predicts response to oral minoxidil treatment for female pattern hair loss
P.M. Ramos, P. Gohad, J. McCoy, C. Wambier, A. Goren
doi : 10.1111/jdv.16765
Volume 35, Issue 1 p. e24-e26
Lack of effect of topical statins in linear porokeratosis
M. Saleva-Stateva, L. Weibel, M. Theiler, M. Balabanova, M. C. Boente, C. Has
doi : 10.1111/jdv.16768
Volume 35, Issue 1 p. e26-e28
Alemtuzumab-induced halo naevus-like hypopigmentation – new insights into secondary skin autoimmunity in response to an immune cell-depleting antibody
M. B?hm, E.H. Kemp, D. Metze, A.M. Muresan, M. Neufeld, R.M. Luiten, T. Ruck
doi : 10.1111/jdv.16781
Volume 35, Issue 1 p. e28-e30
Dupilumab-induced serum sickness-like reaction: an unusual adverse effect in a patient with atopic eczema
R. Treudler, N. Delaroque, M. Puder, J.-C. Simon, M. Szardenings
doi : 10.1111/jdv.16782
Volume 35, Issue 1 p. e30-e32
Hidradenitis suppurativa – prevalence analyses of German statutory health insurance data
S. Schneider-Burrus, G. Lux, K. van der Linde, S. Barbus, J. Huss-Marp, A. Tsaousi, J. Wasem, B. Wolff, R. Sabat
doi : 10.1111/jdv.16783
Volume 35, Issue 1 p. e32-e35
Microenvironment in cutaneous melanomas: a gene expression profile study may explain the role of histological regression
S. Osella-Abate, C. Vignale, L. Annaratone, A. Nocifora, L. Bertero, I. Castellano, G. Avallone, L. Conti, P. Quaglino, F. Picciotto, R. Senetta, M.G. Papotti, P. Cassoni, S. Ribero
doi : 10.1111/jdv.16784
Volume 35, Issue 1 p. e35-e38
Erythema gyratum repens-like eruption after anti-IL-17 therapy of pityriasis rubra pilaris
A.D. Gloor, M. van Rhyn, C. Schlapbach
doi : 10.1111/jdv.16785
Volume 35, Issue 1 p. e38-e40
Localization-mapping of arteriolosclerotic ulcers of Martorell using two-dimensional computational rendering reveals a predominant location on the mid-lateral lower leg
B. Weber, J. Deinsberger, J. Hafner, H. Beltraminelli, S. Tzaneva, K. B?hler
doi : 10.1111/jdv.16787
Volume 35, Issue 1 p. e40-e42
Favourable outcomes in folliculotropic mycosis fungoides after multimodality treatment in a single institution
C.W. Laggis, A. Lamb, A.M. Secrest, N. Ufkes, A.S. Halwani, R. Tao, D. Gaffney, R.R. Miles, S.R. Florell, D. Wada
doi : 10.1111/jdv.16790
Volume 35, Issue 1 p. e42-e45
Diurnal and seasonal variation in psoriasis symptoms
F.J. Ferguson, G. Lada, H.J.A. Hunter, C. Bundy, A.L. Henry, C.E.M. Griffiths, C.E. Kleyn
doi : 10.1111/jdv.16791
Volume 35, Issue 1 p. e45-e47
Histological evidence for epidermal and dermal atrophy of the alopecic band in treatment-naïve patients with Frontal Fibrosing Alopecia
D. Saceda-Corralo, K. Desai, C. Pindado-Ortega, O.M. Moreno-Arrones, S. Va??-Galv?n, M. Miteva
doi : 10.1111/jdv.16792
Volume 35, Issue 1 p. e47-e49
Correlation between electrical impedance spectroscopy and the clinical and dermoscopic grading of actinic keratoses
B.M. Berger, G.R. Giuffrida, Z.I. Zalaudek, E.E. Eber, H.R. Hofmann-Wellenhof
doi : 10.1111/jdv.16793
Volume 35, Issue 1 p. e49-e51
BMI and response to systemic treatment in melanoma metastatic patients
F. Marsan, J.M. Nguyen, E. Varey, C. Fronteau, A. Khammari, B. Dreno
doi : 10.1111/jdv.16794
Volume 35, Issue 1 p. e51-e53
Hair pigment distribution changes after haematopoietic stem cell transplantation in Griscelli syndrome type 2
M.A. Yamazaki-Nakashimada, R. Rold?n-Mar?n, S. Toussaint-Caire, A. Olaya-Vargas, N. Ram?rez-Uribe, F. Rivas-Larrauri, C. Dur?n-McKinster, M.A. Alc?ntara-Ortigoza, A. Gonz?lez-del Angel, L. Orozco-Covarrubias, S. Scheffler-Mendoza, M. Saez-de-Ocariz
doi : 10.1111/jdv.16795
Volume 35, Issue 1 p. e53-e56
Mycoplasma pneumoniae-associated Stevens–Johnson syndrome: characteristic histological features of mucosal lesion
T. Katsumi, N. Hama, Y. Iwai, K. Kimura, O. Ansai, T. Suzuki, R. Abe
doi : 10.1111/jdv.16796
Volume 35, Issue 1 p. e56-e57
A patient with CARD14-associated papulosquamous eruptions showing atopic dermatitis-like features
T. Takeichi, S. Terawaki, Y. Kubota, Y. Ito, K. Tanahashi, Y. Muro, M. Akiyama
doi : 10.1111/jdv.16799
Volume 35, Issue 1 p. e58-e59
Atypical blue naevus of the labium minus confirmed by whole-exome sequencing
K. Katsuo, Y. Kaku, K. Yamamura, Y. Ishida, Y. Endo, G. Egawa, A. Otsuka, K. Kabashima
doi : 10.1111/jdv.16805
Volume 35, Issue 1 p. e59-e61
Monitoring skin metastases during immuno- and targeted therapy using total-body 3D photography
M. Erdmann, L. Heinzerling, G. Schuler, C. Berking, S. Schliep
doi : 10.1111/jdv.16806
Volume 35, Issue 1 p. e61-e63
Determinants of costs and benefits in psoriasis routine care: results from a cross-sectional nationwide study in Germany
N. Zander, M. Naatz, M. Augustin, A. Langenbruch, J. Topp, U. Mrowietz, R. von Kiedrowski, M. Krensel, D. Jungen, N. Kirsten
doi : 10.1111/jdv.16807
Volume 35, Issue 1 p. e63-e65
Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study
R. Rivera, A. Martorell, A. L?pez, L. Salgado, A. Sahuquillo, P. de la Cueva, P. Herranz, J.A. Rat?n, M. Ferr?n, R. Izu, D. Ruiz-Genao, C. Garc?a-Donoso, J.M. Carrascosa
doi : 10.1111/jdv.16809
Volume 35, Issue 1 p. e65-e67
Clinical validation of a computer-based approach for the quantification of the skin ageing process of women using in vivo confocal microscopy
J. Robic, A. Nkengne, B. Perret, M. Couprie, H. Talbot, G. Pellacani, K. Vie
doi : 10.1111/jdv.16810
Volume 35, Issue 1 p. e68-e70
Medicopsis romeroi infection presenting as disseminated nodules and sinuses in a patient with chronic rheumatoid arthritis
A. Bains, S. Singh, N. Dutt, S. Asfahan, D. Vedant, A. Nalwa
doi : 10.1111/jdv.16811
Volume 35, Issue 1 p. e70-e72
Perceptions and attitudes of medical students regarding artificial intelligence in dermatology
S.I. Cho, B. Han, K. Hur, J.-H. Mun
doi : 10.1111/jdv.16812
Volume 35, Issue 1 p. e72-e73
Positive patch testing with omeprazole in Stevens-Johnson syndrome: a case report
E. Van Tendeloo, J. Gutermuth, M. Grosber
doi : 10.1111/jdv.16814
Volume 35, Issue 1 p. e74-e75
Yellow dots in frontal fibrosing alopecia
C.T. Thompson, M.A. Mart?nez-Velasco, A. Tosti
doi : 10.1111/jdv.16820
Volume 35, Issue 1 p. e75-e76
Axitinib-induced scrotal ulcers: a novel cutaneous adverse event
A.A. Stefaniak, E. W?jcik, ?. Matusiak, J.C. Szepietowski
doi : 10.1111/jdv.16821
Volume 35, Issue 1 p. e77-e78
A novel quantitative ELISA as accurate and reproducible tool to detect epidermal transglutaminase antibodies in patients with Dermatitis Herpetiformis
F. Ziberna, D. Sblattero, S. Lega, C. Stefani, M. Dal Ferro, F. Marano, B. Gaita, L. De Leo, S. Vatta, I. Berti, M. Caproni, D. Bonciani, K. Lindfors, T. Salmi, T. Reunala, K. Kaukinen, S. Kalliokoski, K. Kurppa, B. Ura, E. Barbi, M. Bramuzzo, T. Not
doi : 10.1111/jdv.16822
Volume 35, Issue 1 p. e78-e80
CYLD-related cutaneous syndrome: variable p.Pro482fs*6 phenotype in five individuals from two unrelated families
D. Carton de Tournai, I. Vandernoot, M. Marangoni, D. Faverly, M. Diaz, A. Casagranda, E. Berlingin, L. Van Maldergem
doi : 10.1111/jdv.16823
Volume 35, Issue 1 p. e81-e83
Melanocytic nevi in RASopathies: insights on dermatological diagnostic handles
C. Leoni, C. Guerriero, R. Onesimo, V. Coco, C. Di Ruscio, A. Acampora, I. Esposito, A. Romano, M. Tartaglia, M. Genuardi, G. Zampino
doi : 10.1111/jdv.16824
Volume 35, Issue 1 p. e83-e85
Dermatoscopy in tinea capitis: can it provide clues for the responsible fungi?
D. Lekkas, D. Ioannides, E. Lazaridou, A. Lallas, Z. Apalla, E. Vakirlis, E. Sotiriou
doi : 10.1111/jdv.16825
Volume 35, Issue 1 p. e85-e87
The sunburn sign and the suntan sign- two novel findings in Hispanic patients with dermatomyositis
S. Chavez-Alvarez, Y. Suro-Santos, A. Villarreal-Martinez, M.E. Herz-Ruelas, D.A. Galarza-Delgado, I.J. Hernandez-Galarza, M. Gomez-Flores, O.T. Vazquez-Martinez, J. Ocampo-Candiani
doi : 10.1111/jdv.16826
Volume 35, Issue 1 p. e88-e89
Severe thrombocytopenia and excellent response following combined immune checkpoint inhibition for metastatic malignant melanoma
R. Wang, M. Uretzki, D. Boehmer, R. Hein, T. Biedermann, C. Posch
doi : 10.1111/jdv.16829
Volume 35, Issue 1 p. e89-e92
An intraoperative study with ex vivo fluorescence confocal microscopy: diagnostic accuracy of the three visualization modalities
C. Reggiani, G. Pellacani, L. Reggiani Bonetti, G. Zanelli, P. Azzoni, J. Chester, S. Kaleci, B. Ferrari, P. Bellini, C. Longo, L. Bertoni, C. Magnoni
doi : 10.1111/jdv.16831
Volume 35, Issue 1 p. e92-e94
Pre-exposure prophylaxis for HIV infection and new sexually transmitted infections among men who have sex with men: real-life experience from three sexual health clinics in France
M. Colas, C. Vanhaecke, C. Courtieu, D. Lambert, T. Lihoreau, C. Merle, A.R. Schmidt-Guerre, I. Ginet-Mermet, M. Viguier, F. Pelletier, F. Aubin
doi : 10.1111/jdv.16832
Volume 35, Issue 1 p. e94-e96
